Stifel Nicolaus Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lifted by stock analysts at Stifel Nicolaus from $441.00 to $495.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 8.47% from the stock’s previous close.

ALNY has been the subject of a number of other reports. Bank of America upped their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Needham & Company LLC upped their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. UBS Group lifted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Finally, BMO Capital Markets raised their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Twenty-four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $445.35.

Alnylam Pharmaceuticals Trading Down 1.0%

NASDAQ:ALNY opened at $456.35 on Monday. The firm has a market cap of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a 50-day simple moving average of $441.57 and a 200-day simple moving average of $339.95. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,405 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president owned 25,231 shares of the company’s stock, valued at $11,405,673.55. This trade represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last ninety days. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Atlantic Union Bankshares Corp bought a new position in Alnylam Pharmaceuticals in the second quarter worth about $30,000. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $27,000. Bessemer Group Inc. grew its stake in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the period. Elevation Point Wealth Partners LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth $37,000. Finally, Ameritas Advisory Services LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $42,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.